mitochondria pain spinal cord injury

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
02 Jul 2024
Historique:
accepted: 20 06 2024
received: 07 02 2024
revised: 07 06 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

Secondary spinal cord injury (SCI) is characterized by increased cytokines and chemokines at the site of injury that have been associated with the development of neuropathic pain. Nearly 80% of SCI patients report suffering from chronic pain, which is poorly managed with available analgesics. While treatment with the FDA-approved β

Identifiants

pubmed: 38955493
pii: jpet.124.002171
doi: 10.1124/jpet.124.002171
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Ingrid L Peterson (IL)

University of Arizona, United States.

Natalie E Scholpa (NE)

University of Arizona, United States schnell@pharmacy.arizona.edu.

Kiara J Bachtle (KJ)

University of Arizona, United States.

Jennifer B Frye (JB)

University of Arizona, Tucson, United States.

Sanna H Loppi (SH)

University of Arizona, United States.

Austin D Thompson (AD)

University of Arizona, United States.

Kristian Doyle (K)

Immunobiology, Neurology, University of Arizona, Tucson, United States.

Tally Marie Largent-Milnes (TM)

Pharmacology, University of Arizona, United States.

Rick G Schnellmann (RG)

Pharmacology & Toxicology, College of Pharmacy Administration, United States schnell@pharmacy.arizona.edu.

Classifications MeSH